Specific molecular marker for detecting myelodysplastic syndrome, kit and application

Through the specific molecular markers and kits of the LRRFIP1 gene, the problem of complexity of MDS diagnosis is solved, and the accurate diagnosis and prognosis evaluation of myelodysplastic syndrome is achieved, new therapeutic targets are provided, and the accuracy of treatment is improved. sex.

CN119082304APending Publication Date: 2024-12-06JIANGSU PROVINCE HOSPITAL (THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411304010.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-19
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The diagnosis of myelodysplastic syndrome (MDS) is complex and prone to misdiagnosis and misdiagnosis. The existing technology lacks effective specific molecular markers and diagnostic targets, making it difficult to accurately guide the treatment.

Method used

By exploring the nucleotide sequence involved in the LRRFIP1 gene as a specific molecular marker and combining the GAPDH gene as an internal reference, a kit for detecting MDS can be developed, which can isolate the high-expression group and low-expression group of the LRRFIP1 gene in patients with myelodysplastic syndrome. group, guide prognostic evaluation and treatment screening.

Benefits of technology

More accurate diagnosis and prognosis evaluation of MDS patients is achieved, and new therapeutic targets are provided. The treatment is guided through the regulatory mechanism of the LRRFIP1 gene, which improves the diagnostic and treatment accuracy of MDS.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082304A_ABST
    Figure CN119082304A_ABST
Patent Text Reader

Abstract

The invention discloses a specific molecular marker for detecting myelodysplastic syndrome, and relates to the field of molecular biology and clinical application, the specific molecular marker is a nucleotide sequence located in an LRRFIP1 gene, an upstream primer of the specific molecular marker is as shown in SEQ ID NO: 1, a downstream primer of the specific molecular marker is as shown in SEQ ID NO: 2, and an internal reference primer of the specific molecular marker is a GAPDH gene. An upstream primer of a nucleotide sequence in the GAPDH gene is as shown in SEQ ID NO: 3, and a downstream primer is as shown in SEQ ID NO: 4. The specific regulation and control mechanism of the LRRFIP1 in the myelodysplastic syndrome is researched, so that the diagnosis, treatment and prognosis evaluation of the LRRFIP1 in a patient with the myelodysplastic syndrome are better guided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of molecular biology and clinical application, and in particular to a specific molecular marker, a kit and an application thereof for detecting myelodysplastic syndrome. Background Art

[0002] Myelodysplastic syndrome (MDS) is an acquired hematopoietic stem cell clonal proliferative disease characterized by abnormal differentiation or development of one or more myeloid cell lines, manifested as refractory cytopenia, ineffective hematopoiesis, and hematopoietic failure, with a high risk of transformation to acute myeloid leukemia (AML). In recent years, the incidence of MDS has shown an upward trend. More than half of MDS patients are over 75 years old, and the incidence of MDS increases with age. With the increasing aging of my country, MDS will cause an increasingly serious burden on society. Since MDS is a highly heterogeneous malignant tumor derived from hematopoietic stem cells, the diagnosis of MDS is a complex and unstructured process, so it is easy to cause missed diagnosis and misdiagnosis. Therefore, actively exploring the pathogenesis and progression mechanism of MDS and striving to find new targets for the diagnosis and treatment of MDS are key issues that need to be solved urgently.

[0003] At present, there are few studies at home and abroad on the regulation of the LRRFIP1 gene involved in the pathogenesis of MDS. Through previous studies, it was found that the MDS CpG island methylation phenotype composed of leucine-rich repeat-interacting protein 1 (LRRFIP1) is an independent prognostic factor for MDS. LRRFIP1 is an oncogene. The LRRFIP1 protein can bind to the Dvl protein and participate in the regulation of signal transduction, cell proliferation, apoptosis and cell cycle. The research team found in previous studies and many previous studies that abnormal activation of the canonical Wnt pathway is involved in the occurrence and development of MDS. Dishevelled (Dvl) protein mediates canonical and non-canonical Wnt signal transduction through specific protein domains. Summary of the invention

[0004] One of the purposes of the present invention is to provide a specific molecular marker for detecting myelodysplastic syndrome, which has solved the problems of missed diagnosis and misdiagnosis caused by the complex and unstructured diagnosis of myelodysplastic syndrome in the prior art, and to find new targets for the diagnosis and treatment of myelodysplastic syndrome by exploring the pathogenesis and progression mechanism of myelodysplastic syndrome.

[0005] The present invention is achieved through the following technical scheme: a specific molecular marker for detecting myelodysplastic syndrome, wherein the specific molecular marker is a nucleotide sequence located in the LRRFIP1 gene.

[0006] Furthermore, the upstream primer of a nucleotide sequence located in the LRRFIP1 gene is shown as 5'-CACCAGATGACAGG ACCAGAACTC-3' (SEQ ID NO: 1), and the downstream primer is shown as 5'-TGTGCCTGCCTGCTCTTCAAC-3' (SEQ ID NO: 2).

[0007] Furthermore, the specific molecular marker also includes an internal reference primer, and the internal reference primer is the GAPDH gene.

[0008] Furthermore, the upstream primer of the nucleotide sequence in the GAPDH gene is shown as 5'-AGATCATCAGCAATGCCTCCT-3' (SEQ ID NO: 3), and the downstream primer is shown as 5'-TGAGTCCTTCCACGATACCAA-3' (SEQ ID NO: 4).

[0009] Another aspect of the present invention provides a kit for detecting myelodysplastic syndrome, the kit comprising a detection substance of the LRRFIP1 gene, a reaction solution, a precipitant, a stop solution, a linear standard, and the specific molecular marker as described in any one of the above items.

[0010] Furthermore, the kit may also include a detection substance for detecting the expression level of the LRRFIP1 gene.

[0011] Furthermore, the kit may also include a module for realizing the following functions: detecting the expression level of the LRRFIP1 gene in a sample group of adult patients with myelodysplastic syndrome, taking the median value of the expression level of the sample group, and dividing the patients into a LRRFIP1 gene low expression group and a LRRFIP1 gene high expression group; defining the LRRFIP1 gene low expression group as a myelodysplastic syndrome prognosis low risk group, and defining the LRRFIP1 gene high expression group as a myelodysplastic syndrome prognosis medium-high risk group.

[0012] In another aspect, the present invention provides a use of a kit for detecting myelodysplastic syndrome. According to the kit described above, it has any of the following uses: (1) use in the prognosis assessment of human myelodysplastic syndrome; (2) use in the determination of human myelodysplastic syndrome.

[0013] In another aspect, the present invention provides a use of the specific molecular marker as described above in the preparation and screening of therapeutic drugs for myelodysplastic syndrome.

[0014] In another aspect, the present invention provides a use of the specific molecular marker as described above in the preparation of a drug for myelodysplastic syndrome, wherein the drug is a drug for treating myelodysplastic syndrome.

[0015] In another aspect, the present invention provides a use of the specific molecular marker as described above in the preparation of a detection reagent for diagnosis, treatment and prognosis assessment of myelodysplastic syndrome.

[0016] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0017] 1. The present invention provides the application of LRRFIP1 gene as a specific molecular marker for myelodysplastic syndrome. By studying the specific regulatory mechanism of LRRFIP1 in myelodysplastic syndrome (MDS), better guidance is achieved on the diagnosis, treatment and prognosis evaluation of LRRFIP1 in patients with myelodysplastic syndrome (MDS).

[0018] 2. The present invention first observed in SKM-1 cell lines and MUTZ-1 cell lines that overexpression of LRRFIP1 can promote cell proliferation and inhibit cell apoptosis. Subsequently, mRNA transcriptome sequencing revealed that LRRFIP1 can participate in regulating the Wnt / β-catenin signaling pathway, and a dual luciferase reporter gene experiment (TOP flash / FOP flash) confirmed that LRRFIP1 can positively regulate the activity of the Wnt / β-catenin signaling pathway.

[0019] 3. The present invention confirms that LRRFIP1 is a new potential biomarker through bioinformatics analysis and verification in myelodysplastic syndrome (MDS) cell lines. It can be used for the diagnosis, treatment and prognosis evaluation of patients with myelodysplastic syndrome (MDS) and guide the precise diagnosis and treatment of patients. In addition, this molecular marker can also be used to develop drugs for the treatment of MDS or to screen drugs for the treatment of myelodysplastic syndrome. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] The drawings described herein are used to provide a further understanding of the embodiments of the present invention, constitute a part of this application, and do not constitute a limitation of the embodiments of the present invention. In the drawings:

[0021] Figure 1 This is the cell proliferation status in the LRRFIP1 silenced expression and overexpression MDS cell lines provided in Example 1 of the present invention.

[0022] Figure 2 This is a diagram of the cell apoptosis in LRRFIP1 silenced expression and overexpression MDS cell lines detected by the Annexin-V APC / 7-AAD double staining method provided in Example 1 of the present invention.

[0023] Figure 3The flow cytometry provided in Example 1 of the present invention was used to detect cell apoptosis in MDS cell lines with silent expression and overexpression of LRRFIP1.

[0024] Figure 4 This is a diagram of cell apoptosis in MDS cell lines with silent expression and overexpression of LRRFIP1 detected by TUNEL method provided in Example 1 of the present invention.

[0025] Figure 5 This is a diagram of the cell cycle in MDS cell lines with silent expression and overexpression of LRRFIP1 detected by the PI single staining method provided in Example 1 of the present invention.

[0026] Figure 6 This is a graph showing the effect of different expressions of LRRFIP1 on the Wnt / β-catenin signaling pathway in transcriptome analysis provided in Example 2 of the present invention.

[0027] Figure 7 This is a diagram of immunoprecipitation detection in the MDS cell line provided in Example 3 of the present invention.

[0028] Figure 8 This is a graph of the activity of the Wnt / β-catenin signaling pathway in LRRFIP1 overexpressing and silent expression cell lines using dual luciferase reporter genes as provided in Example 3 of the present invention.

[0029] Fig. 9 This is a diagram of the Wnt signaling pathway detected by qRT-PCR and Western blot provided in Example 3 of the present invention.

[0030] Fig.10 This is a diagram of the gene and protein expression levels of LRRFIP1 / Dvl3 co-expressed in the MUTZ-1 cell line provided in Example 3 of the present invention.

[0031] Fig.11 This is a diagram showing cell proliferation in the LRRFIP1 / Dvl3 co-overexpressing cell line and the LRRFIP1 overexpressing / Dvl3 silencing co-transfected MDS cell line provided in Example 4 of the present invention.

[0032] Fig.12 This is a diagram of cell apoptosis in LRRFIP1 / Dvl3 co-overexpressing cell lines and LRRFIP1 overexpressing / Dvl3 silencing co-transfected MDS cell lines detected by Annexin-V APC / 7-AAD double staining provided in Example 4 of the present invention.

[0033] Fig.13 This is a diagram of cell apoptosis in the LRRFIP1 overexpression / Dvl3 silenced expression MDS cell line provided in Example 4 of the present invention.

[0034] Fig.14 This is a diagram of cell apoptosis in MDS cell lines detected by TUNEL method provided in Example 4 of the present invention.

[0035] Fig.15 This is a diagram of the cell cycle in the LRRFIP1 / Dvl3 co-overexpressing cell line detected by PI single staining provided in Example 4 of the present invention. DETAILED DESCRIPTION

[0036] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments.

[0037] Unless otherwise specified, all technical and scientific terms used herein have the same meanings as commonly understood by those skilled in the art in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe methods and / or materials related to the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail. Regarding the "comprising", "including", "having", "containing" and the like used herein, they are all open-ended terms, that is, they mean including but not limited to. Unless the context clearly indicates otherwise, the expressions "a" and "one" used herein include plural references. For example, referring to "a cell" includes a plurality of such cells and equivalents known to those skilled in the art, etc. The term "about" used herein means a range of ±20% of the value thereafter. In some embodiments, the term "about" means a range of ±10% of the value thereafter. In some embodiments, the term "about" means a range of ±5% of the value thereafter; the term "MDS" means myelodysplastic syndrome; the term "cell line" means a cell population that is cultured in vitro for a long term and can proliferate indefinitely.

[0038] Embodiment 1,

[0039] This example is used to illustrate the effect of LRRFIP1 gene on cell biological characteristics in myelodysplastic syndrome (MDS) cell lines.

[0040] Step 1: Construction of LRRFIP1 overexpression and silenced expression cell lines: In this study, a LRRFIP1 lentiviral overexpression vector was constructed and transfected into the MDS cell line to obtain a LRRFIP1 stable overexpression cell line. At the same time, three LRRFIP1 small interfering RNAs (siRNAs) were constructed to select the most stable silenced expression cell line.

[0041] Step 2: Effect of LRRFIP1 on cell proliferation: In this study, 3,000 cells of the control group, si-LRRFIP1, oe-LRRFIP1 SKM-1, and MUTZ-1 cells were plated in a 96-well plate, and 3 additional wells were set up. CCK-8 reagent was added 2d, 4d, 6d, 8d, and 10d after plating, and the absorbance was measured after incubation for 1h, and the proliferation curve was drawn based on the results.

[0042] According to the results Figure 1 , Cell proliferation in LRRFIP1 silenced and overexpressed MDS cell lines, from Figure 1 As can be seen, the cell proliferation in the LRRFIP1 overexpression cell line was significantly higher than that in the LRRFIP1 silenced expression cell line.

[0043] Step 3: Effect of LRRFIP1 on cell apoptosis: After treating cells with Annexin V and 7-AAD double staining, flow cytometry was used to detect the occurrence of cell apoptosis. TUNEL was also used to detect cell apoptosis. The lower right quadrant Q1 of the scatter plot represents early apoptotic cells, the upper right quadrant Q2 represents late apoptotic cells, the upper left quadrant Q3 represents necrotic cells, and the lower left quadrant Q4 represents normal living cells.

[0044] Figure 2 The figure shows the cell apoptosis in LRRFIP1 silenced expression and overexpression MDS cell lines detected by Annexin-V APC / 7-AAD double staining method.

[0045] Figure 3 The figure shows the cell apoptosis detected by flow cytometry in LRRFIP1 silenced expression and overexpression MDS cell lines.

[0046] Figure 4 The figure shows the cell apoptosis in MDS cell lines with LRRFIP1 silenced expression and overexpression detected by TUNEL method.

[0047] from Figures 2~4 As can be seen from the figure, the apoptosis rate of the LRRFIP1 overexpressing cell line was significantly lower than that of the LRRFIP1 silencing expression cell line.

[0048] Step 4: Effect of LRRFIP1 on cell cycle: PI single staining method was used to detect the cell cycle. The results are as follows Figure 5 As shown, Figure 5The cell cycle in MDS cell lines with LRRFIP1 silenced expression and overexpression detected by PI single staining is shown. It can be seen from the figure that in the SKM-1 line, the proportion of cells in the S phase and G2 phase when LRRFIP1 is overexpressed is 31.44% and 17.85%, respectively, while the proportion of cells in the S phase is significantly increased (47.22%) when LRRFIP1 is silenced, and the proportion of cells in the G2 phase is significantly decreased (12.56%). Therefore, LRRFIP1 silenced expression can lead to cell cycle arrest in the S phase. In the MUTZ-1 cell line, the proportion of cells in the S phase and G2 phase in the LRRFIP1 overexpression cell line is 44.54% and 21.71%, respectively, while the proportion of cells in the S phase and G2 phase when LRRFIP1 is silenced is 32.74% and 9.14%, respectively.

[0049] In summary, it can be seen from this example that overexpression of the LRRFIP1 gene can promote cell proliferation, and silenced expression of the LRRFIP1 gene can cause cell cycle arrest at the G1 / S phase and induce cell apoptosis.

[0050] Embodiment 2,

[0051] In this example, transcriptomics was used to analyze the effects of different expression levels of the LRRFIP1 gene on the Wnt / β-catenin signaling pathway.

[0052] Step 1: The LRRFIP1-overexpressing SKM-1 cell line, the LRRFIP1-silenced SKM-1 cell line, and the untreated SKM-1 cell line (three replicates each) were analyzed using mRNA transcriptome sequencing technology.

[0053] Step 2: Sequencing obtains the FPKM value corrected for gene length and sequencing depth to characterize the expression level of each gene, and uses a box plot to display the expression level distribution results of each sample (such as Figure 6 -A) shows that the gene expression distribution of the 9 samples is similar and comparable. At the same time, the principal component analysis (PCA) of the mRNA of these 9 samples was performed. The PCA graph shows that the center points of the three groups do not overlap, indicating that the three groups of samples have obvious distinctions, and the samples within the group have good reproducibility and cluster together, indicating that there are obvious differences in mRNA expression among the three groups (such as Figure 6 -B). We also display the correlation coefficients between samples using heat maps, and the results can guide the judgment of sample differences between groups and sample duplication within the same group. Figure 6 As shown in Figure 2-C, the correlation between samples within each group is the strongest, indicating that the repeatability of samples within the group is good. The correlation between samples between groups is weak, indicating that there are differences in gene expression between different groups.

[0054] Step 3: Perform GO enrichment analysis on differentially expressed genes (DEGs). Figure 6 The bubble chart shown in -D shows the 20 most significantly enriched biological processes of differentially expressed genes in SKM-1 cell lines with overexpression of LRRFIP1 gene compared with untreated cells. KEGG analysis of differentially expressed genes was also performed. Figure 6 The bubble plot shown in -E shows the 20 most significantly enriched signaling pathways of differentially expressed genes in SKM-1 cell lines with LRRFIP1 overexpression versus untreated cells. Enrichment analysis was also performed using Reactome, confirming that LRRFIP1 is involved in the positive regulation of the Wnt / β-catenin signaling pathway.

[0055] Figure 6 A~E in the figure show the effect of different expression of LRRFIP1 on Wnt / β-catenin signaling pathway in transcriptome analysis, where (A) is a box plot of gene expression FPKM distribution, the vertical axis is log10(FPKM), the horizontal axis is one sample per region, and the statistics contained in the box plot are maximum value, Q75, Q50, Q25 and minimum value from top to bottom; (B) is the result of principal component analysis, the horizontal axis represents the first principal component, and the vertical axis represents the second principal component; (C) is a heat map of correlation between samples, the horizontal and vertical axes are The symbol is the square value of the correlation coefficient; (D) is the GO analysis diagram of differentially expressed genes, which shows the 20 most significantly enriched biological processes of differentially expressed genes in SKM-1 cell lines with overexpression of LRRFIP1 versus untreated cells; (E) is the KEGG analysis diagram of differentially expressed genes, which shows the 20 most significantly enriched signal pathways of differentially expressed genes in SKM-1 cell lines with overexpression of LRRFIP1 versus untreated cells; (F) is the Reactome enrichment analysis confirming that overexpression of LRRFIP1 positively regulates the canonical Wnt signaling pathway.

[0056] Embodiment 3,

[0057] In this example, the Wnt / β-catenin signaling pathway was regulated by co-expression of LRRFIP1 and Dvl.

[0058] Step 1: Interaction between LRRFIP1 protein and Dvl protein in MDS cell lines: This study selected two proteins in Dvl (Dvl2 and Dvl3 proteins) and used co-immunoprecipitation technology to detect whether there is interaction between LRRFIP1 protein and Dvl protein in SKM-1 and MUTZ-1 cell lines. The results showed that LRRFIP1 protein interacts with Dvl2 protein and Dvl3 protein in SKM-1 and MUTZ-1 cell lines. Figure 7The immunoprecipitation detection diagram in the MDS cell line is shown, from which it can be seen that there is interaction between the LRRFIP1 protein and the Dvl2 protein and the Dvl3 protein, wherein Input is a positive control; IgG is a negative control; and IP is immunoprecipitation.

[0059] Step 2: Construction of Dvl3 overexpression and silenced expression cell lines: In this study, a Dvl3 lentiviral overexpression vector was constructed and transfected into the MDS cell line to obtain a Dvl3 stable overexpression cell line. At the same time, three Dvl3 small interfering RNAs (siRNAs) were constructed to select the most stable silenced expression cell line.

[0060] Step 3: Construction of LRRFIP1 / Dvl3 co-overexpression and LRRFIP1 overexpression / Dvl3 silenced expression cell lines: LRRFIP1 overexpression vector and Dvl3 overexpression vector were co-transfected into MDS cell lines to obtain LRRFIP1 / Dvl3 co-overexpression MDS cell lines. At the same time, LRRFIP1 overexpression vector and Dvl3 siRNA-3 were co-transfected into MDS cell lines to obtain LRRFIP1 overexpression / Dvl3 silenced expression MDS cell lines.

[0061] Step 4: In addition to verifying the gene expression levels of LRRFIP1 in LRRFIP1 overexpression, silenced expression, LRRFIP1 / Dvl3 co-overexpression and LRRFIP1 overexpression / Dvl3 silenced expression cell lines by qRT-PCR, and Dvl3 in Dvl3 overexpression, silenced expression, LRRFIP1 / Dvl3 co-overexpression and LRRFIP1 overexpression / Dvl3 silenced expression cell lines, the protein expression levels of LRRFIP1 and Dvl3 in the corresponding overexpression and silenced expression cell lines were also verified by Western blot, which was consistent with the qRT-PCR verification results.

[0062] Step 5: Explore the involvement of LRRFIP1 gene in the regulation of Wnt / β-catenin signaling pathway in MDS in cell lines.

[0063] Step 6: LRRFIP1 overexpression activates Wnt / β-catenin signaling pathway: The dual luciferase reporter gene experiment (TOP flash / FOP flash) was used to determine the effect of different expression levels of LRRFIP1 on the activity of the classical Wnt signaling pathway. In MDS cell lines, LRRFIP1 overexpression significantly increased the TOP flash activity of the Wnt signaling pathway, while the TOP flash activity was significantly reduced in the cell line where LRRFIP1 was silenced, indicating that LRRFIP1 plays an active role in the regulation of the Wnt / β-catenin signaling pathway. Figure 8The figure shows the activity of Wnt / β-catenin signaling pathway in LRRFIP1 overexpressing and silenced cell lines detected by dual luciferase reporter gene.

[0064] Step 7: LRRFIP1 and Dvl3 positively synergistically regulate the Wnt / β-catenin signaling pathway: Similarly, the interaction between LRRFIP1 and Dvl3 in the canonical Wnt signaling pathway was detected by dual luciferase reporter gene experiments. When LRRFIP1 was overexpressed alone, TOP flash activity was increased. When the two overexpression vectors were co-transfected, the TOP flash activity was significantly different from that when LRRFIP1 was overexpressed alone; and when LRRFIP1 overexpression / Dvl3 silenced expression was co-transfected, TOP flash activity was significantly decreased, indicating that LRRFIP1 and Dvl can synergistically enhance the activity of the canonical Wnt signaling pathway.

[0065] Step 8: Changes in gene and protein expression of Wnt pathway (including Dvl2, Dvl3, β-catenin, GSK-3β and Wnt) in SKM-1 cell lines with different expression levels of LRRFIP1 and co-expression of LRRFIP1 / Dvl3: LRRFIP1 overexpression significantly upregulated non-phosphorylated β-catenin, Dvl2, Dvl3 and Wnt at the mRNA level. At the protein level, LRRFIP1 overexpressed in SKM-1 cell lines significantly upregulated the expression level of non-phosphorylated β-catenin protein, while Dvl2 protein, Dvl3 protein and Wnt protein had no significant difference between the two groups with different LRRFIP1 expression. Compared with LRRFIP1 overexpression / Dvl3 silencing, LRRFIP1 / Dvls co-overexpression significantly upregulated non-phosphorylated β-catenin, GSK-3β and Wnt at the mRNA level, and the expression levels of β-catenin protein, GSK-3β protein and Wnt protein were also significantly upregulated. Fig. 9 A diagram of the Wnt signaling pathway detected by qRT-PCR and Western blot is shown, including the gene and protein expression levels of Dvl2, Dvl3, β-catenin, GSK-3β, and Wnt in LRRFIP1-differently expressed and LRRFIP1 / Dvl3-co-expressing SKM-1 cell lines.

[0066] Step 9: Changes in gene and protein expression of Wnt pathway (including Dvl2, Dvl3, β-catenin, GSK-3β and Wnt) in MUTZ-1 cell line with different expression levels of LRRFIP1 and co-expression of LRRFIP1 / Dvl3: Overexpression of LRRFIP1 in MUTZ-1 cell line significantly upregulated the expression levels of non-phosphorylated β-catenin protein, Dvl2 protein, Dvl3 protein and Wnt protein, which was consistent with the mRNA expression levels of these genes in this cell line. These results all indicate that LRRFIP1 can positively regulate the transduction of Wnt signaling pathway. Compared with LRRFIP1 overexpression / Dvl3 silencing expression, LRRFIP1 / Dvls co-overexpression significantly upregulated non-phosphorylated Dvl2, β-catenin and Wnt at the mRNA level. The expression levels of Dvl2 protein, β-catenin protein, GSK-3β protein and Wnt protein were also significantly upregulated. These results indicate that LRRFIP1 and Dvl can synergistically enhance the transduction of the Wnt signaling pathway. Fig.10 A diagram of the Wnt signaling pathway detected by qRT-PCR and Western blot is shown, from which the gene and protein expression levels of Dvl2, Dvl3, β-catenin, GSK-3β and Wnt in the LRRFIP1 different expression and LRRFIP1 / Dvl3 co-expression MUTZ-1 cell lines can be seen.

[0067] Embodiment 4,

[0068] This example illustrates the effect of co-expression of LRRFIP1 and Dvl3 on cell biological characteristics.

[0069] Step 1: Effect of LRRFIP1 and Dvl3 co-expression on cell proliferation: CCK8 was used to detect the difference in cell proliferation in LRRFIP1 / Dvl3 co-overexpression cell lines and LRRFIP1 overexpression / Dvl3 silenced expression co-transfection cell lines. The cell proliferation in the LRRFIP1 / Dvl3 co-overexpression cell line was significantly higher than that in the LRRFIP1 overexpression / Dvl3 silenced expression co-transfection cell line. Fig.11 The graph shows the cell proliferation in the LRRFIP1 / Dvl3 co-overexpressing cell line and the LRRFIP1 overexpressing / Dvl3 silencing co-transfected MDS cell line.

[0070] Step 2: Effect of LRRFIP1 and Dvl3 co-expression on cell apoptosis: After treating cells with Annexin V and 7-AAD double staining, flow cytometry was used to detect the occurrence of cell apoptosis. At the same time, TUNEL was used to detect cell apoptosis. This study compared the differences in cell apoptosis in LRRFIP1 / Dvl3 co-overexpression cell lines and LRRFIP1 overexpression / Dvl3 silenced expression co-transfection cell lines. The apoptosis rate in LRRFIP1 / Dvl3 co-overexpression cell lines was significantly lower than that in LRRFIP1 overexpression / Dvl3 silenced expression co-transfection cell lines. This is consistent with the above cell proliferation detection results.

[0071] Fig.12 The figure shows the cell apoptosis in the LRRFIP1 / Dvl3 co-overexpressing cell line and the LRRFIP1 overexpressing / Dvl3 silencing co-transfected MDS cell line detected by Annexin-V APC / 7-AAD double staining method.

[0072] Step 3: Effect of LRRFIP1 and Dvl3 co-expression on cell cycle: In SKM-1 cell line, compared with LRRFIP1 overexpression / Dvl3 silenced expression co-transfection (the proportion of cells in S phase and G2 phase were 22.12% and 21.76%, respectively), the proportion of cells in S phase and G2 phase in LRRFIP1 / Dvl3 co-overexpression cell line was 37.60% and 16.25%, respectively, indicating that LRRFIP1 / Dvl3 co-overexpression can promote cell proliferation. In MUTZ-1 cell line, the proportion of cells in S phase and G2 phase in LRRFIP1 / Dvl3 co-overexpression cell line was 42.17% and 24.39%, respectively, and the proportion of cells in S phase and G2 phase in LRRFIP1 overexpression / Dvl3 silenced expression co-transfection cell line was 35.30% and 13.48%, respectively, which also confirmed that LRRFIP1 / Dvl3 co-overexpression can promote cell proliferation.

[0073] Fig.13 The figure shows the apoptosis of cells in LRRFIP1 / Dvl3 co-overexpressing cell lines and LRRFIP1 overexpressing / Dvl3 silencing MDS cell lines detected by flow cytometry. Fig.14 The figure shows the cell apoptosis detected by TUNEL method in LRRFIP1 / Dvl3 co-overexpressing cell lines and LRRFIP1 overexpressing / Dvl3 silent expressing MDS cell lines. Fig.15The cell cycle of the LRRFIP1 / Dvl3 co-overexpressing cell line and the LRRFIP1 overexpressing / Dvl3 silencing MDS cell line detected by PI single staining is shown. From the above figure and the description of this embodiment, it can be seen that the LRRFIP1 / Dvl3 co-overexpression can promote cell proliferation, while the LRRFIP1 overexpression / Dvl3 silencing expression can cause the cell cycle to be arrested in the G1 phase and induce cell apoptosis.

[0074] The above examples firstly observed in SKM-1 cell lines and MUTZ-1 cell lines that overexpression of LRRFIP1 can promote cell proliferation and inhibit cell apoptosis.

[0075] Subsequent mRNA transcriptome sequencing revealed that LRRFIP1 can participate in regulating the Wnt / β-catenin signaling pathway.

[0076] Dual luciferase reporter gene assay (TOP flash / FOP flash) confirmed that LRRFIP1 can positively regulate the activity of the Wnt / β-catenin signaling pathway. Dvl enhances the activity of the Wnt signaling pathway by stabilizing the β-catenin / TCF transcription complex, which is essential for the transduction of the Wnt / β-catenin signaling pathway.

[0077] To further explore whether LRRFIP1 regulates the Wnt / β-catenin signaling pathway by interacting with Dvl, we used co-immunoprecipitation technology to confirm that LRRFIP1 protein interacts with Dvl protein.

[0078] Subsequently, LRRFIP1 overexpression / silencing expression and Dvl3 overexpression / silencing expression plasmids were constructed to obtain the corresponding stable expression cell lines. At the same time, LRRFIP1 / Dvl3 co-overexpression and LRRFIP1 overexpression / Dvl3 silencing expression cell lines were also constructed. Dual luciferase reporter gene experiments confirmed that LRRFIP1 and Dvl can synergistically enhance the activity of the Wnt / β-catenin signaling pathway.

[0079] At the same time, the effects of different expression levels of LRRFIP1 on apoptotic proteins (BCL-2, Caspase-3) and cell cycle proteins (CyclinD1, p21) were also detected. The expression of BCL-2 protein and CyclinD1 protein in LRRFIP1 overexpression cell lines was significantly higher than that in LRRFIP1 silenced expression cell lines; on the contrary, the expression of Caspase-3 protein and p21 protein in LRRFIP1 overexpression cell lines was significantly lower than that in LRRFIP1 silenced expression cell lines; it also confirmed that LRRFIP1 overexpression can promote cell proliferation and inhibit cell apoptosis.

[0080] In summary, combined with Examples 1 to 4, it can be seen that LRRFIP1 is generally considered to be an oncogene, and its encoded protein can bind to Dvl protein and participate in the regulation of signal transduction, cell proliferation, apoptosis and cell cycle. However, there are few studies on the regulation of the LRRFIP1 gene involved in the pathogenesis of MDS at home and abroad. Examples 1 to 4 provide further evidence for exploring the pathogenesis of MDS and provide new basis for finding new diagnostic and therapeutic targets for MDS.

[0081] Based on the above embodiments, products using the LRRFIP1 gene molecular marker are provided in the following embodiments.

[0082] Embodiment 5,

[0083] This embodiment provides a specific molecular marker for detecting myelodysplastic syndrome.

[0084] Specifically, the specific molecular marker is a nucleotide sequence located in the LRRFIP1 gene. The upstream primer of the nucleotide sequence in the LRRFIP1 gene is shown in SEQ ID NO:1, and the downstream primer is shown in SEQ ID NO:2.

[0085] Specifically, the specific molecular marker also includes an internal reference primer, which is the GAPDH gene. The upstream primer of the nucleotide sequence in the GAPDH gene is shown in SEQ ID NO:3, and the downstream primer is shown in SEQ ID NO:4.

[0086] Embodiment 6,

[0087] In this embodiment, a kit for detecting myelodysplastic syndrome is provided.

[0088] The kit provided in this example includes a detection substance of the LRRFIP1 gene, a reaction solution, a precipitant, a stop solution, a linear standard, and the specific molecular marker and internal reference primer described in Example 5.

[0089] The kit may also contain a detection substance for detecting the expression level of the LRRFIP1 gene.

[0090] In this embodiment, the kit may further include a module for realizing the following functions: detecting the expression level of the LRRFIP1 gene in a sample group of adult myelodysplastic syndrome patients, taking the median value of the expression level of the sample group, and dividing the patients into a LRRFIP1 gene low expression group and a LRRFIP1 gene high expression group.

[0091] The LRRFIP1 gene low expression group was defined as the myelodysplastic syndrome low-risk prognosis group, and the LRRFIP1 gene high expression group was defined as the myelodysplastic syndrome medium-high risk prognosis group.

[0092] The kit provided in this embodiment can be used in the prognosis assessment of human myelodysplastic syndrome or the diagnosis of human myelodysplastic syndrome.

[0093] The specific implementation methods described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific implementation method of the present invention and is not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A specific molecular marker for detecting myelodysplastic syndrome, characterized in that the specific molecular marker is a nucleotide sequence located in the LRRFIP1 gene.

2. The specific molecular marker for detecting myelodysplastic syndrome according to claim 1, characterized in that: The upstream primer of the nucleotide sequence located in the LRRFIP1 gene is shown as SEQ ID NO:1, and the downstream primer is shown as SEQ ID NO:

2.

3. The specific molecular marker for detecting myelodysplastic syndrome according to claim 1, characterized in that: The specific molecular marker also includes an internal reference primer, which is the GAPDH gene. The upstream primer of the nucleotide sequence in the GAPDH gene is shown in SEQ ID NO:3, and the downstream primer is shown in SEQ ID NO:

4.

4. A kit for detecting myelodysplastic syndrome, characterized in that: The kit comprises a detection substance of the LRRFIP1 gene, a reaction solution, a precipitant, a stop solution, a linear standard, and the specific molecular marker according to any one of claims 1 to 3.

5. The kit for detecting myelodysplastic syndrome according to claim 4, characterized in that: The kit also contains a detection substance for detecting the expression amount of the LRRFIP1 gene.

6. The kit for detecting myelodysplastic syndrome according to claim 4, characterized in that: The kit also includes a module that implements the following functions: The expression of LRRFIP1 gene was detected in the sample group of adult patients with myelodysplastic syndrome, and the median value of the expression of the sample group was taken to divide the patients into a low expression group of LRRFIP1 gene and a high expression group of LRRFIP1 gene; The LRRFIP1 gene low expression group was defined as the myelodysplastic syndrome low-risk prognosis group, and the LRRFIP1 gene high expression group was defined as the myelodysplastic syndrome medium-high risk prognosis group.

7. An application of a kit for detecting myelodysplastic syndrome, characterized in that: The kit according to any one of claims 4 to 6, which has any of the following uses: (1) Application in the prognosis assessment of human myelodysplastic syndrome; (2) Application in diagnosis of human myelodysplastic syndrome.

8. Use of the specific molecular marker according to any one of claims 1 to 3 in preparing and screening therapeutic drugs for myelodysplastic syndrome.

9. Use of a specific molecular marker according to any one of claims 1 to 3 in the preparation of a drug for myelodysplastic syndrome, characterized in that: The medicine is a medicine for treating myelodysplastic syndrome.

10. Use of the specific molecular marker according to any one of claims 1 to 3 in the preparation of a detection reagent for diagnosis, treatment and prognosis assessment of myelodysplastic syndrome.